Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Activation of the Amino Acid Response Pathway Blunts the Effects of Cardiac Stress.

Qin P, Arabacilar P, Bernard RE, Bao W, Olzinski AR, Guo Y, Lal H, Eisennagel SH, Platchek MC, Xie W, Del Rosario J, Nayal M, Lu Q, Roethke T, Schnackenberg CG, Wright F, Quaile MP, Halsey WS, Hughes AM, Sathe GM, Livi GP, Kirkpatrick RB, Qu XA, Rajpal DK, Faelth Savitski M, Bantscheff M, Joberty G, Bergamini G, Force TL, Gatto GJ Jr, Hu E, Willette RN.

J Am Heart Assoc. 2017 May 9;6(5). pii: e004453. doi: 10.1161/JAHA.116.004453.

2.

Soluble epoxide hydrolase inhibition does not prevent cardiac remodeling and dysfunction after aortic constriction in rats and mice.

Morgan LA, Olzinski AR, Upson JJ, Zhao S, Wang T, Eisennagel SH, Hoang B, Tunstead JR, Marino JP Jr, Willette RN, Jucker BM, Behm DJ.

J Cardiovasc Pharmacol. 2013 Apr;61(4):291-301. doi: 10.1097/FJC.0b013e31827fe59c.

PMID:
23232840
3.

Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress.

Costell MH, Ancellin N, Bernard RE, Zhao S, Upson JJ, Morgan LA, Maniscalco K, Olzinski AR, Ballard VL, Herry K, Grondin P, Dodic N, Mirguet O, Bouillot A, Gellibert F, Coatney RW, Lepore JJ, Jucker BM, Jolivette LJ, Willette RN, Schnackenberg CG, Behm DJ.

Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012.

4.

GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo.

Behm DJ, Aiyar NV, Olzinski AR, McAtee JJ, Hilfiker MA, Dodson JW, Dowdell SE, Wang GZ, Goodman KB, Sehon CA, Harpel MR, Willette RN, Neeb MJ, Leach CA, Douglas SA.

Br J Pharmacol. 2010 Sep;161(1):207-28. doi: 10.1111/j.1476-5381.2010.00889.x.

5.

Chronic inhibition of hypoxia-inducible factor prolyl 4-hydroxylase improves ventricular performance, remodeling, and vascularity after myocardial infarction in the rat.

Bao W, Qin P, Needle S, Erickson-Miller CL, Duffy KJ, Ariazi JL, Zhao S, Olzinski AR, Behm DJ, Pipes GC, Jucker BM, Hu E, Lepore JJ, Willette RN.

J Cardiovasc Pharmacol. 2010 Aug;56(2):147-55. doi: 10.1097/FJC.0b013e3181e2bfef.

PMID:
20714241
6.

Pharmacological inhibition of C-C chemokine receptor 2 decreases macrophage infiltration in the aortic root of the human C-C chemokine receptor 2/apolipoprotein E-/- mouse: magnetic resonance imaging assessment.

Olzinski AR, Turner GH, Bernard RE, Karr H, Cornejo CA, Aravindhan K, Hoang B, Ringenberg MA, Qin P, Goodman KB, Willette RN, Macphee CH, Jucker BM, Sehon CA, Gough PJ.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):253-9. doi: 10.1161/ATVBAHA.109.198812. Epub 2009 Dec 3. Erratum in: Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):e170.

PMID:
19965779
7.

In vivo serial assessment of aortic aneurysm formation in apolipoprotein E-deficient mice via MRI.

Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Karr HW, Mirabile RC, Willette RN, Gough PJ, Jucker BM.

Circ Cardiovasc Imaging. 2008 Nov;1(3):220-6. doi: 10.1161/CIRCIMAGING.108.787358. Epub 2008 Sep 17.

PMID:
19808546
8.

Assessment of macrophage infiltration in a murine model of abdominal aortic aneurysm.

Turner GH, Olzinski AR, Bernard RE, Aravindhan K, Boyle RJ, Newman MJ, Gardner SD, Willette RN, Gough PJ, Jucker BM.

J Magn Reson Imaging. 2009 Aug;30(2):455-60. doi: 10.1002/jmri.21843.

PMID:
19629967
9.

Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.

Willette RN, Eybye ME, Olzinski AR, Behm DJ, Aiyar N, Maniscalco K, Bentley RG, Coatney RW, Zhao S, Westfall TD, Doe CP.

J Pharmacol Exp Ther. 2009 Sep;330(3):964-70. doi: 10.1124/jpet.109.154443. Epub 2009 Jun 25.

PMID:
19556450
10.

p38 MAPK inhibition reduces aortic ultrasmall superparamagnetic iron oxide uptake in a mouse model of atherosclerosis: MRI assessment.

Morris JB, Olzinski AR, Bernard RE, Aravindhan K, Mirabile RC, Boyce R, Willette RN, Jucker BM.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):265-71. Epub 2007 Dec 27.

PMID:
18162612
11.

Selective PPARdelta agonist treatment increases skeletal muscle lipid metabolism without altering mitochondrial energy coupling: an in vivo magnetic resonance spectroscopy study.

Jucker BM, Yang D, Casey WM, Olzinski AR, Williams C, Lenhard SC, Legos JJ, Hawk CT, Sarkar SK, Newsholme SJ.

Am J Physiol Endocrinol Metab. 2007 Nov;293(5):E1256-64. Epub 2007 Aug 28.

12.

PPARdelta activation normalizes cardiac substrate metabolism and reduces right ventricular hypertrophy in congestive heart failure.

Jucker BM, Doe CP, Schnackenberg CG, Olzinski AR, Maniscalco K, Williams C, Hu TC, Lenhard SC, Costell M, Bernard R, Sarov-Blat L, Steplewski K, Willette RN.

J Cardiovasc Pharmacol. 2007 Jul;50(1):25-34.

PMID:
17666912
13.

P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.

Nerurkar SS, Olzinski AR, Frazier KS, Mirabile RC, O'Brien SP, Jing J, Rajagopalan D, Yue TL, Willette RN.

Biomarkers. 2007 Jan-Feb;12(1):87-112.

PMID:
17438656
14.

Differential uptake of ferumoxtran-10 and ferumoxytol, ultrasmall superparamagnetic iron oxide contrast agents in rabbit: critical determinants of atherosclerotic plaque labeling.

Yancy AD, Olzinski AR, Hu TC, Lenhard SC, Aravindhan K, Gruver SM, Jacobs PM, Willette RN, Jucker BM.

J Magn Reson Imaging. 2005 Apr;21(4):432-42.

PMID:
15779033
15.

Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection.

Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, Coatney RW, Willette RN.

Cardiovasc Res. 2005 Apr 1;66(1):170-8. Epub 2005 Jan 28.

PMID:
15769460
16.

Cathepsin S expression is up-regulated following balloon angioplasty in the hypercholesterolemic rabbit.

Burns-Kurtis CL, Olzinski AR, Needle S, Fox JH, Capper EA, Kelly FM, McQueney MS, Romanic AM.

Cardiovasc Res. 2004 Jun 1;62(3):610-20.

PMID:
15158154
17.

p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension.

Ju H, Behm DJ, Nerurkar S, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, Willette RN.

J Pharmacol Exp Ther. 2003 Dec;307(3):932-8. Epub 2003 Oct 15.

PMID:
14561851
18.

Sustained activation of p38 mitogen-activated protein kinase contributes to the vascular response to injury.

Ju H, Nerurkar S, Sauermelch CF, Olzinski AR, Mirabile R, Zimmerman D, Lee JC, Adams J, Sisko J, Berova M, Willette RN.

J Pharmacol Exp Ther. 2002 Apr;301(1):15-20.

PMID:
11907152
19.

Enrasentan improves survival, limits left ventricular remodeling, and preserves myocardial performance in hypertensive cardiac hypertrophy and dysfunction.

Willette RN, Anderson KM, Nelson AH, Olzinski AR, Woods T, Coatney RW, Aiyar N, Ohlstein EH, Barone FC.

J Cardiovasc Pharmacol. 2001 Oct;38(4):606-17.

PMID:
11588531

Supplemental Content

Loading ...
Support Center